Avecho Expands Phase III Insomnia Trial with New Recruitment Sites

The latest announcement is out from Avecho Biotechnology Limited ( (AU:AVE) ).

Avecho Biotechnology Limited announced the commencement of recruitment at new sites in Sydney and the Gold Coast for its Phase III clinical trial of a CBD TPM-enhanced capsule aimed at treating insomnia. The company has partnered with Sandoz AG to accelerate patient recruitment and prepare for regulatory submissions, marking a significant milestone in the trial’s progress. The collaboration is expected to leverage Sandoz’s expertise to enhance trial execution and potentially expedite the product’s path to market, benefiting stakeholders by potentially shortening timelines for TGA registration.

More about Avecho Biotechnology Limited

Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from Vitamin E and enhances the solubility and absorption of drugs and nutrients. Avecho’s lead asset is a proprietary cannabidiol (CBD) TPM soft-gel capsule currently undergoing Phase III clinical development for insomnia treatment.

Current Market Cap: A$14.28M

For a thorough assessment of AVE stock, go to TipRanks’ Stock Analysis page.